COMPARISON OF SURVIVAL TIME BETWEEN SMALL CELL LUNG CANCER PATIENTS WITHOUT AND WITH METASTASIS IN DIFFERENT ORGANS

Hoàng Tiến Mạnh; Nguyễn Thị Thanh

COMPARISON OF SURVIVAL TIME BETWEEN SMALL CELL LUNG CANCER PATIENTS WITHOUT AND WITH METASTASIS IN DIFFERENT ORGANS

About this article

Received: 01/04/21 Revised: 28/04/21 Published: 29/04/21

Authors

1. Hoang Tien Manh , Vietnam Military Medical University
2. Nguyen Thi Thanh, E Hospital

Abstract

Small cell lung cancer is a dangerous disease threatening human life and health. This study was performed to evaluate the risk factors for distant metastasis and the effect of metastasis in different organs on survival in the patient. Patient data were collected from SEER database between 2010-2016. A retrospective study design was used in this study. 4933 patients were screened for analysis, of which 2316 patients had metastases, accounting for 46.9%. During follow-up, 3990 (80.9%) of patients died, of which 3707 (92.9%) died from lung cancer, only 283 (17.1%) died from diseases or causes. Whether or not the patient had metastasis was closely related to age, sex, stage T-stage, N-stage, surgery of primary site, and radiation therapy (P<0.05). Mean survival time in the non-metastatic group was 13 months, in the groups of patients with metastasis were 9 months (lung), 8 months (bone), 7 months (brain), 7 months (liver), and 6 months (multi-organ). Distal metastasis showed a poor prognosis in patients with small cell lung cancer. The difference in prognosis between groups of patients had statistical significance, the order of their survival times was: no metastasis > lung metastasis > bone metastasis, brain metastasis, liver metastasis > multi-organ metastasis.

Keywords

Tumor; Small cell lung cancer; Metastasis; Survival time; Radiation therapy

Full Text:

PDF (Tiếng Việt)

References

[1] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, "Cancer Statistics, 2021," CA Cancer J Clin, vol. 71, no. 1, pp. 7-33, 2021.

[2] N. Howlader et al., "SEER Cancer Statistics Review, 1975-2013, National Cancer Institute." Bethesda, MD, 2013. [Online]. Available: https://seer.cancer.gov/archive/csr/1975_2013/. [Accessed Dec. 12, 2020].

[3] T. Sher, G. K. Dy, and A. A. Adjei, "Small cell lung cancer," Mayo Clin Proc, vol. 83, no. 3, pp. 355-67, 2008.

[4] S. N. Waqar and D. Morgensztern, "Treatment advances in small cell lung cancer (SCLC)," Pharmacol Ther, vol. 180, pp. 16-23, 2017.

[5] M. Riihimäki et al., "Metastatic sites and survival in lung cancer," Lung Cancer, vol. 86, no. 1, pp. 78-84, 2014.

[6] D. H. Pham, V. T. Tran, and T. C. Dang, "Cancer registry results in some regions in Vietnam in the 2006-2007 period," Ho Chi Minh city medicine, vol. 13, no. 5, pp. 53-64, 2009.

[7] H. Rief et al., "Survival and prognostic factors in non-small cell lung cancer patients with spinal bone metastases: a retrospective analysis of 303 patients," Strahlenther Onkol, vol. 190, no. 1, pp. 59-63, 2014.

[8] C. Kan, G. Vargas, F. L. Pape, and P. Clézardin, "Cancer Cell Colonisation in the Bone Microenvironment," Int J Mol Sci, vol. 17, no. 10, pp. 1674, 2016.

[9] E. Schapira et al., "Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases," Int J Radiat Oncol Biol Phys, vol. 101, no. 3, pp. 624-629, 2018.

[10] S. Sung, S. W. Lee, Y. K. Kwak, J. H. Kang, S. H. Hong, and Y. S. Kim, "Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer," J Neurooncol, vol. 139, no. 1, pp. 205-213, 2018.

[11] C. Zhang, C. Liao, B. C. Penney, D. E. Appelbaum, C. A. Simon, and Y. Pu, "Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images," Radiology, vol. 275, no. 3, pp. 862-869, 2015.

[12] V. T. Tran, V. Q. Le, and T. Q. Nguyen, Guidelines for diagnosis and treatment of common cancers. Medical Publishing House, 2019.

[13] Y. K. Chae et al., "Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer," Clin Lung Cancer, vol. 18, no. 2, pp. 132-140, 2017.

Refbacks

There are currently no refbacks.



Remember me